Sign Out
Pregnancy: There are no adequate and well-controlled studies for the use of NIMEDINE in pregnant women.
The potential risk for humans is unknown.
NIMEDINE should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Breastfeeding: Imipenem and cilastatin are excreted into the mother's milk in small quantities. Little absorption of either compound occurs following oral administration. Therefore it is unlikely that the suckling infant will be exposed to significant quantities. If the use of NIMEDINE is deemed necessary, the benefit of breastfeeding for the child should be weighed against the possible risk for the child.
